SEC Comment Letter for REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589) (REGN) — Mar 31, 2015
REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589)
Date: March 31, 2015 · CIK: 0000872589 · Accession: 0000000000-15-018741
AI Filing Summary & Sentiment
Letter
March 30 , 2015 Via E -mail Robert E. Landry Senior Vice President of Finance - Chief Financial Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591
Re: Regeneron Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 16, 2015 File No. 000 -19034
Dear Mr. Landry:
We have completed our review of your filing. We remind you that our comment s or changes to disclo sure in response to our comment s do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the feder al securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable ru les require.
Sincerely,
/s/ Bryan J. Pitko for
Show Raw Text
March 30 , 2015 Via E -mail Robert E. Landry Senior Vice President of Finance - Chief Financial Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591 Re: Regeneron Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 16, 2015 File No. 000 -19034 Dear Mr. Landry: We have completed our review of your filing. We remind you that our comment s or changes to disclo sure in response to our comment s do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the feder al securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable ru les require. Sincerely, /s/ Bryan J. Pitko for Jeffrey P. Riedler Assistant Director